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A Case of Open Angle Glaucoma Secondary  
to Posner-Schlossman Syndrome
ABSTRACT
This is a case report demonstrating the appropriate diagnosis and man-
agement of PSS and its potential sequelae. Posner-Schlossman Syndrome 
is characterized by recurrent, unilateral attacks of significantly increased 
intraocular pressure. The etiology and pathophysiology of this condition 
remains unclear. Duration of this chronic condition and the risk of devel-
oping secondary open angle glaucoma are directly proportional. The pa-
tient and managing optometrist must be aware of the necessity of timely 
intervention during acute attacks, as well as adherent longitudinal care to 
preserve function and quality of life. The ensuing case report and review 
underscores the impact of this disease.
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INTRODUCTION
Posner-Schlossman Syndrome (PSS) was first described as a glaucomatocyclitic crisis by Terrien and Veil in 
1929 and was later re-named for Adolph Posner and Abraham Schlossman after their case series of nine pa-
tients with the condition.1,2 PSS typically affects young to middle-aged individuals between the ages of 20 
and 50, although there are reports involving adolescents and patients older than 70.3–5 PSS is diagnosed by its 
clinical presentation, which is characterized by an idiopathic, recurrent, unilateral and self-limiting attack 
of increased intraocular pressure (IOP) accompanied by mild non-granulomatous anterior uveitis. PSS may 
include mild patient symptoms such as visual blur and eye pain.1,3 Slit lamp evaluation may detect minimal ke-
ratic precipitates with rare cell and flare in the anterior chamber; posterior synechiae is unlikely.3 Gonioscopic 
evaluation reveals an open angle without peripheral anterior synechiae formation, and keratic precipitates 
may also be seen.3 
Patients with PSS characteristically have IOPs surpassing 40mmHg during their attacks. Readings will often 
be much higher, although slightly lower IOPs have also been reported.6 The literature shows mean IOP rang-
ing between 42.77 and 49.20mmHg.6–8 Between the recurrent PSS attacks, which tend to resolve within days 
to weeks, glaucoma-associated parameters remain within normal limits.9 However, as many as 45% of PSS 
patients have been shown to have associated open angle glaucoma (OAG).6 The development of OAG caused by 
repeated attacks of PSS has been noted throughout the literature.3,6,10 
In a retrospective non-comparative case series on the clinical course of 53 PSS patients with an average dura-
tion of seven years, 26.4% were diagnosed as having developed OAG secondary to PSS.3 The literature reports 
that patients who have had PSS for more than 10 years have a 2.8-fold greater risk of developing glaucoma than 
their counterparts who have had the disease less than 10 years.6 The following case demonstrates the appropri-
ate diagnosis and management of PSS and its possible sequelae.
CASE REPORT
A 49-year-old African-American male was originally diagnosed with PSS OS by an outside provider in 1997, and 
with OAG secondary to recurrent cyclitic attacks OS by our clinic in 2013. The patient had a documented history of 
poor compliance with longitudinal care and inconsistently presented during PSS attacks for management. This pa-
tient’s highest recorded intraocular pressures (IOP) were 18mmHg OD and 38mmHg OS by Goldmann applanation 
tonometry (GAT or TAG) during his most recent cyclitic attack in February 2016. He was treated with loteprednol 
0.5% one drop eight times per day and continued timolol twice per day OS in response to that attack. He returned 
in a week with a normalized IOP of 10mmHg in the OS and the resolution of ocular signs consistent with his attack.
The patient presented in August 2016 for a glaucoma follow-up and reported adherent use of 0.5% timolol maleate 
twice daily in his left eye. The patient denied flashes, floaters, haloes, headaches, double vision, burning, itching, red-
ness and tearing in either eye. He believed that his PSS attacks coincided with the control of his systemic conditions.
 His medical history was pertinent for chronic shoulder pain (post rotator cuff surgery) and knee pain due to os-
teoarthritis, migraines and depressive disorder. A diagnosis of seronegative (<8.6 IU/mL) rheumatoid arthritis (RA) 
was made in 2001. However, there was a debate amongst his rheumatologists whether his diagnosis was seronega-
tive RA or mixed connective tissue disease (MCTD), as the patient is (+)ANA (antinuclear antibody test) and (+)
RNP (ribonucleoprotein). The patient is currently followed by rheumatology every three months. There is no rel-
evant family ocular or systemic history.
The examination in August 2016 revealed 20/20 visual acuity OD and OS. There were no defects involving the pu-
pils, extraocular muscles or confrontation fields. Slit lamp examination was remarkable only for trace fine keratic 
precipitates and 0.5 anterior chamber reaction OS (AC grade per Standardization of Uveitis Nomenclature (SUN) 
working group), with the irises intact and of equal color OU. IOP in office measured 17mmHg OD and 10mmHg OS 
@1:07pm. Dilated fundus exam (DFE) showed a right optic nerve head measuring 1.50mm vertically (with a 66D 
funduscopic lens) with a 0.55V/0.55H C/D. The lamina exhibited no major reconfiguration, the neuroretinal rim 
was intact 360 and RNFL was diffuse and symmetrical in both the superior and inferior hemispheres. The left optic 
nerve head measured 1.50mm vertically using a 66D lens with a 0.85V/0.80H C/D. There was concentric erosion of 
the rim with posterior laminar excavation and striate reconfiguration. The residual rim appeared perfused and the 
RNFL grossly exhibited diffuse inferior thinning in excess of that found in its superior counterpart. (Figures 1 and 
2) The periphery was flat, intact and had no holes, tears, or detachments OU. 
C A NA D I A N  JO U R NA L  o f  O P T O M E T RY    |    R EV U E  C A NA D I E N N E  D ’O P T O M É T R I E     VO L .  8 1   NO.  330
CASE REPORT
Additional testing determined the patient’s central corneal thickness to be 544/557μm OD, OS. Corneal hysteresis and 
corneal compensated IOP (IOPcc) were 8.2 and 18.3mmHg, respectively, OD, and 8.6 and 11.4mmHg, respectively, OS. 
The most recent gonioscopy, using the Shaffer classification, was grade 4 with a wide open angle to ciliary body with 
1+ trabecular meshwork pigmentation 360’ OD and a grade 3 open angle to scleral spur with 1+ pigmentation 360’ 
with no synechiae OS. Trabecular meshwork was notably clear in both eyes. Visual field testing was done and reli-
able in both eyes (Figure 3). The right eye had a mean deviation of +0.37dB and no glaucomatous defects. The left 
eye had a mean deviation of -2.66dB with 3 local defects within the nasal step region of <1% probability on pattern 
deviation. This was consistent with past findings. Optical coherence tomography (Spectralis®, Heidelberg Engineer-
ing GmbH, Heidelberg, Germany), specifically circumpapillary RNFL (cp-RNFL), of the OD had a global thickness 
of 92 um, which was unchanged from a previous scan one year earlier. The OS scan had a global cp-RNFL thickness 
of 55 um, which was also unchanged from April 2015 (Figure 4). A posterior pole asymmetry analysis (PPAA) scan 
showed severe thinning of the total retinal thickness OS compared to OD (Figure 5). The average total retinal thick-
ness by PPAA was 287 um OD and 267 um OS. 
Figure 1: Posterior pole photos showing OS RNFL asymmetry superior > inferior.
Fig 1. Posterior Pole photos showing OS RNFL 
asymmetry superior > inferior. 
Figure 2: 20’ ONH photos. OS exhibits concentric neuro-retinal rim loss and substantial laminar reconfiguration.
Fig 2. 20’ ONH photos. OS exhibits concentric neuro-retinal rim loss and substantial 
laminar reconfiguration. 
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Figure 4: Circumpapillary RNFL (cp-RNFL) analysis OD and OS. Note significant thinning globally as well as in the ST  
and IT sectors OS.
Fig 4. Circumpapillary RNFL (cp-
RNFL) analysis OD and OS. Note 
significant thinning globally as 
well as in ST and IT sectors OS. 
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Figure 5: Posterior pole asymmetry analysis shows severe depression in both the superior and inferior arcuate regions OS.
Fig 5. Posterior pole asymmetry analysis shows severe depression in both 
superior and inferior arcuate regions OS. 
At the conclusion of the exam, the patient’s PSS and SOAG were considered to be stable. The patient was in-
structed to continue timolol 0.5% b.i.d. OS and scheduled to return in three months for a glaucoma progress 
visit. The patient was educated to seek care immediately if a new attack occurred. Lastly, he was educated that 
the relationship between his RA/MCTD and PSS has not yet been described in the literature, and any connec-
tion between the two was dubious.
DISCUSSION
 The exact mechanism of increased IOP in PSS is unknown.9 It is understood that, in cases of inflammatory 
open angle glaucoma, trabecular meshwork (TM) obstruction is the most common mechanism of increased 
IOP. TM obstruction is followed by hypersecretion of aqueous and mediated by prostaglandins E1 and E2 (PGE1 
and 2).11 Specifically, the blood-aqueous barrier is disrupted, which permits an influx of inflammatory cells into 
the aqueous and leads to the harboring of normal serum components in the outflow system. Trabeculitis likely 
develops, resulting in pore-narrowing and dysfunction, further obstructing aqueous outflow.9 Significantly 
elevated aqueous prostaglandin levels have been documented during the acute phase of PSS. This increased 
PGE concentration causes a concomitant rise in the aqueous protein concentration and subsequent increased 
aqueous viscosity.11 Increased aqueous production coupled with decreased aqueous outflow results in a sub-
stantial increase in IOP.12
The precise etiology and pathophysiology of PSS are also still unclear.3,13 Several potential causes have been 
proposed, with more recent theories focusing on viral etiologies for PSS. Additional mechanisms that have 
been explored include an abnormal vascular response, autosomal defects, and oxidative damage of the trabecu-
lar meshwork.3,13
Research on possible viral etiologies for PSS has recently focused on cytomegalovirus (CMV). This focus be-
gan because studies using PCR have shown that up to 75% of aqueous samples from immunocompetent PSS 
patients were positive for CMV viral DNA during active attacks.7,13–16 Interestingly, further PCR exploration of 
aqueous samples from PSS patients during inactive periods found that all patients were negative for CMV viral 
DNA.16 These results are compelling and possibly suggestive of an association between intraocular CMV infec-
tion and PSS in healthy patients. However, the virtually universal sero-prevalence of human CMV precludes a 
conclusion of causation at this time.7,8,17 Although real-time quantitative detection of CMV by plasma PCR has 
increased the sensitivity and specificity of testing, there is no consensus that would support routinely ordering 
this bloodwork in patients with PSS.18 
Despite evidence associating CMV infection with PSS, the ultimate clinical inflammatory reaction appears to 
be immune-mediated and not infectious in nature.18 While trabeculitis is thought to occur, the precise patho-
physiological mechanism for this response is unknown. In a study of 53 immunocompetent uveitis patients 
with clinical signs of PSS, aqueous samples were compared to those of 25 healthy control patients for the pres-
ence or absence of CMV viral DNA, as well as cytokine concentrations. Over 97% of PSS samples were distin-
guished from controls by elevated cytokine levels, not CMV. The authors found that the presence or absence 
of CMV was not significantly associated with different aqueous cytokine concentrations in these patients.18 
This pro-immune inflammatory conclusion is consistent with PSS’s classic hyper-response to corticosteroid 
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treatment, which helps differentiate PSS from other forms of CMV uveitis that fail to respond to steroids.19 In 
our patient, both of his proposed systemic conditions (RA and MCTD) are, not surprisingly, associated with an 
increased production of a range of cytokines.20,21 However, PSS has not been studied in cohorts similar to our 
patient. 
Vascular endothelial dysfunction is a known risk factor for both primary open angle glaucoma and normal tension 
glaucoma. It has also been proposed to be involved in PSS.8,22 A small, prospective case-control study in 2010 involv-
ing 12 patients with PSS and 15 controls was undertaken to evaluate brachial artery endothelium-dependent flow-
mediated dilation (FMD) as an indicator of vascular endothelial function.22 The results showed that FMD in the PSS 
group was much lower than that in the control group. The authors concluded that these results imply peripheral 
vascular endothelial dysfunction in patients with PSS.22 It has been proposed that this endothelial dysfunction could 
predispose PSS patients to developing glaucomatous optic neuropathy secondary to their IOP spikes.8 Further stud-
ies will be needed to advance these speculations.
The role that genetic factors play in the etiology of PSS has also been explored. In 2015, a study on the association 
of human leukocyte antigens (HLA) allelic diversity revealed that the frequency of HLA-C*1402 in PSS patients 
was significantly higher than that in controls.23 Although the cohort was comprised of a southern Chinese popu-
lation and the results have not been validated outside of this population, these findings suggest that genetic im-
mune regulation may play a role in these patients. The rate of PSS in Japan and Singapore ranges from 1.7-4.3% 
of all uveitis diagnoses, which is similar to the findings in northern Europe.8 Although this point has not been 
extensively researched, it seems reasonable that, based on similar global rates of the same condition, a genetic 
component may be universal.
The exclusion of differential diagnoses of hypertensive uveitis is the key to successful patient management. 
Other viral etiologies for uveitis, including herpes simplex and herpes zoster, can present similarly to PSS. 
In these cases, as in PSS, elevated IOP may result from normal aqueous production combined with impaired 
outflow due to an inflamed trabecular meshwork.24 The incidence of elevated IOP in herpetic keratouveitis 
cases has been reported to be up to 43%.25 However, unlike with PSS, these entities will typically present 
with more pronounced symptoms of pain and photophobia and additional anterior segment signs. Herpes sim-
plex uveitis presents with corneal dendrites, iris atrophy, and large keratic precipitates.26 Herpes zoster virus 
(HZV)-associated uveitis will present with corneal pseudodendrites. Most often, these patients have a prior 
instance of a dermatological zoster condition.26 Further confirmation of HZV can be made by testing corneal 
sensation, which will be markedly decreased. Fuchs heterochromic iridocyclitis (FHI) is another important 
and, arguably, most confounding differential diagnosis. FHI, like PSS, presents unilaterally with signs of mild 
inflammation and mild patient symptoms.27 In fact, iris heterochromia can develop in PSS, further complicat-
ing diagnosis and management.17,27 However, unlike PSS, FHI tends to be chronic and refractory to steroids, 
manifests lower IOP and often develops posterior subcapsular cataract.7,27 Finally, although this is not com-
mon, acute angle closure should be considered. In contrast to PSS, acute angle closure presents with a sudden 
increase in intraocular pressure, shallow anterior chamber, and narrowed-to-closed anterior chamber angles.3 
Nausea, corneal edema and severe ocular pain are symptoms that are most commonly associated with an acute 
angle closure event–all of which are inconsistent with PSS.3,28 
Following an accurate diagnosis of PSS, treatment is aimed at managing both the inflammation and IOP eleva-
tion.3,8 Apraclonidine hydrochloride 1% has been universally shown to cause a rapid decrease in IOP within an 
hour of instillation, leading multiple authors to instill it during acute PSS attacks.29,30 Additional IOP-lowering 
medications, such as beta-blockers and carbonic anhydrase inhibitors, are also commonly used to treat acute 
attacks.3 Topical corticosteroids are dosed at a minimum of 4-6 times per day, as recommended in the litera-
ture, followed by a rapid taper.3,31 Rapid taper is justifiable due to the typical self-limiting short course of PSS 
attacks ranging from days to weeks.3 The managing physician must additionally be aware that corticosteroid 
use administered to mitigate inflammation during acute attacks can actually result in a paradoxical decrease 
in the facility of aqueous outflow, which raises IOP.11 No previous study has addressed the superiority or inferi-
ority of one topical corticosteroid versus another in the specific management of PSS. The self-limiting nature 
of PSS attacks helps justify our use of loteprednol, which is known to have a substantially lower likelihood of 
inducing clinically meaningful IOP elevation.32 All of the known topical steroids have the potential to cause 
steroid-induced glaucoma.33
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Timely reduction of IOP during attacks with the above agents is imperative as negative optic disc topography 
and flowmetry changes that result from substantially elevated IOP are reversible.34,35 There is no compelling 
evidence to prescribe chronic low-dose topical steroids in patients with PSS, since they have not been shown 
to reduce the frequency or severity of attacks. Additionally, the chronic use of IOP-lowering agents has not 
been shown to be effective at preventing PSS recurrence and therefore is not necessary in the absence of co-
existing POAG or resulting SOAG.3 Furthermore, there are no guidelines for setting a target pressure in PSS 
patients who develop glaucoma. We subscribe to Jampel’s conceptual description of target IOP: “That IOP at 
which the quality of life (QOL) from preserved vision and the QOL from not having side effects from treatment 
is maximized”.36
The use of antiviral medications in the management of PSS has been investigated following more recent re-
search focusing on CMV as a primary etiology for the disease. The elimination of CMV from the anterior 
chamber using valgancyclovir can modify the disease by reducing IOP, the number of medications used, con-
trolling inflammation, and lowering the recurrence rate8,37–39 A retrospective study comparing topical, oral, and 
intravitreal valgancyclovir in patients with uveitis secondary to CMV showed a higher failure rate (36% topical 
v. 9% oral) but decreased rate of recurrence in the topical group over 27.7 months of followup.39 The study used 
0.15% ganciclovir gel, commercially available internationally as Virgan (known as Zirgan in the United States). 
The recurrence of uveitis once medications were discontinued approached 75%, likely as a result of valganci-
clovir being virostatic rather than virocidal.8,39 A study on the long-term use (3 months) of compounded topical 
2% ganciclovir in 68 eyes of CMV+ PSS patients found that treatment was effective for clearing the viral load, 
helping to control IOP, and preserving the corneal endothelium.40 The authors proposed that early implemen-
tation of ganciclovir could lower the risk of advanced glaucoma and limit the need for surgery in chronically 
recurrent cases.40 
A retrospective observational case study from 2014 was conducted on 11 patients with clinically diagnosed 
PSS who were previously refractory to acyclovir. These patients were subsequently treated with 900mg of oral 
valganciclovir twice daily for three weeks, followed by 450mg twice daily for a mean of 20 months. Notably, 6 
of the 11 patients underwent anterior chamber taps and 5 of these 6 were positive for CMV on PCR analysis. In 
7 of the 11 patients, valganciclovir led to resolution of inflammatory activity and stable IOP. This permitted ta-
pering and discontinuation of valganciclovir in 6 of the 7. Although two patients had inflammatory recurrences 
and needed retreatment, only one remained on reduced therapy. Ultimately, no recurrences were observed 
during the 10-month post-treatment observation period in the patients who responded to valganciclovir. The 
authors concluded that a course of at least 12 months of oral valganciclovir might reduce the recurrence rate in 
patients who continue to relapse on topical ganciclovir or short-term oral valganciclovir.38
Given the results of these multiple case studies, it has been suggested that there should be a low threshold for 
anterior chamber tap in patients whose PSS attacks are not improving and suggestive of CMV infection.8 Further-
more, the concurrent empirical use of topical ganciclovir in these cases has been suggested, followed by a minimum 
3-month course of oral medications if there is a poor response to topical medications.8 Although currently accepted 
methods of management are still primary, the ability to have positive outcomes with anti-CMV agents may repre-
sent an important future option in the management of PSS patients with recurrent disease. Unfortunately, there are 
no clinically detectable differences between CMV+ and CMV– patients in PSS, so it is still difficult to identify which 
patients will benefit from more invasive testing.41
Surgical intervention may be indicated in PSS cases that show increased attack frequency, when IOP fluctuations 
during attacks are significant, or in cases where there is progressive glaucomatous damage to the optic nerve 
and/or visual field due to uncontrolled IOP.3 Filtration surgery has been shown to be successful in PSS cases. 
A 2001 study involving 9 patients with PSS undergoing trabeculectomy with mitomycin C (MMC) showed an 
80% success rate in reducing the frequency of PSS events as well as preventing IOP spikes during the cyclitic 
attacks.6 Consistent with PSS, the patients undergoing filtration in the above study required no anti-glaucoma or 
anti-inflammatory treatment between episodes.6 A possible explanation for why filtration is successful in these 
cases is that inflammatory cells migrate through the postoperative bleb, thus reducing anterior chamber activity 
and trabeculitis, and possibly protect the bleb from failure.6,8 However, surgical therapy should involve careful 
consideration as outcomes may not improve and the condition may even worsen postoperatively. In uveitic glau-
coma patients, conjunctival cellular changes such as increased fibroblast, lymphocyte, and macrophage counts 
have been implicated in surgical failure in patients who have undergone filtration.2 Filtration surgery is associ-
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ated with postoperative complications such as wound leak, flat anterior chamber, hypotony, choroidal effusion, 
hemorrhage, hyphema and infection.42 
Recently, trabeculectomy ab interno (trabectome) has been assessed as another, less invasive, surgical option 
for patients on oral valgancyclovir with uncontrolled CMV+ PSS. Seven patients underwent trabectome sur-
gery and were followed for 12 months postoperatively. The mean IOP before surgery was 40± 10mmHg and the 
number of anti-glaucoma medications used was 3.1±0.4. Post-surgical mean IOP was 13±1 mm and number of 
medications was reduced to 0.8±1.42 This technique may hold promise in patients with chronically uncontrolled 
IOPs experiencing progressive glaucomatous damage. A 2014 study compared trabeculectomy with MMC, tra-
beculotomy and trabectome in patients with uveitic glaucoma. The surgical success rates were 82.86%, 62.5% 
and 75.0% for trabeculectomy, trabeculotomy, and trabectome, respectively.43 The favorable comparison of 
trabeculectomy and trabectome further supports the value of trabectome in these cases. Although surgical 
intervention in patients with OAG secondary to PSS has been shown to be a viable management option, there 
are no consensus guidelines on when surgery should be pursued. Global risk assessment, progression analysis, 
individual patient and doctor risk-tolerance, and potential quality of life adjustments with and without surgi-
cal intervention should be considered prior to pursuing consultation for surgery.
CONCLUSION
PSS is a complex, poorly understood condition that may cause glaucomatous optic neuropathy, as demon-
strated in our case. It is incumbent on the clinician to make an accurate diagnosis amongst multiple differential 
diagnoses, educate the patient to seek urgent care during cyclitic attacks to limit damage, assess IOP between 
attacks, monitor for the development and progression of secondary OAG, and appropriately refer for more ag-
gressive interventions when medical management is unsuccessful. A commonly asked question is whether or 
not PSS is benign. Given the variability of this disease, its sequelae are patient-dependent and involve several 
factors, as outlined in this paper. In our case, PSS was not benign, which further underscored the need for vigi-
lance in the longitudinal care of these patients to maintain functional vision and quality of life. l
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